Personalis (PSNL) said a study showed the "high sensitivity" of its NeXT Personal test for detecting early-stage non-small cell lung cancer.

Preoperative blood samples from 171 patients were analyzed using NeXT Personal, which aims to detect small traces of circulating tumor DNA in the blood of cancer patients and survivors, the company said Monday in a statement.

Detected in the study were 100% of non-adenocarcinomas and 81% of lung adenocarcinomas, previously "one of the most challenging to detect in blood samples because of low ctDNA shedding," Personalis said.

The study results suggest the potential for using the test in managing lung cancer, the company said.

London's Francis Crick Institute and University College London collaborated in the study funded by Cancer Research UK.

Price: 5.52, Change: -0.07, Percent Change: -1.25